SEER Seer Bio Year-over-year net earnings per share growth for the last 12 months

Seer, Inc. leads the proteomics field by implementing the Proteograph AI platform for deep protein analysis. The quarterly EPS growth rate illustrates the fundamental resilience of the business, where 23.80 represents the latest metric reading. Revenues are based on the sale of high-margin consumables for the instruments. Independence from macroeconomic trends makes the company a reliable defensive asset within the medical research sector.

seer.bio (SEER) Year-over-year net earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for Seer, Inc. (SEER)

- share price and expert price forecast:

Stock Price Seer Bio|SEER - Consensus Target

- market capitalization data:

Market Valuation Seer, Inc.|SEER - Value Adjusted for Debt and Cash

- book capitalization indicators:

Net Assets per Single Share Seer|SEER - Company Net Assets|Market Capitalization to Book Value Ratio seer.bio|SEER - Company Assets

- business debt structure and liquidity details:

- earnings and market multiples details:

SEER - Company Net Income|Future Profit Seer, Inc.|SEER - Company Value to Net Income|Forward P/E Multiple Seer Inc|SEER - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Seer|SEER - Operating profit before depreciation charges|Net earnings per share for the last 12 months Seer|SEER - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth seer.bio|SEER - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Seer, Inc.

- revenue and sales proceeds data:

SEER - Company Annual Revenue|Company Projected Revenue Seer Bio|SEER - Market Cap to Revenue|Forward P/S Multiple Seer Inc.

Analysis of all company metrics:Seer Bio - SEER

For Seer, Inc. (SEER), whose competitive edge is based on patented protein analysis, quarterly net income growth per share serves as an indicator of the commercialization of complex technologies. This metric tracks EPS growth dynamics daily, bridging the time gaps between official reports. This chart allows for an assessment of how the expansion of the certified laboratory network impacts profitability. Rising values confirm business scaling, while peak indicators signal risks of the asset becoming overbought.

Main competitors